Depression treatment for West Palm Beach — measurement-based, 28 minutes away.

RECO Health is the closest specialist-level PHP and IOP depression program to West Palm Beach — 18 miles and about 28 minutes down I-95 from El Cid, Flamingo Park, and downtown WPB. Care is measurement-based: every plan opens with a DSM-5-TR formulation and a baseline PHQ-9, and every medication decision is reviewed against that trajectory in weekly psychiatric rounds. When two adequate antidepressant trials fail, clients move to a defined escalation pathway — rTMS at 120% MT, IV ketamine at 0.5 mg/kg, or esketamine — rather than a fifth trial-and-error prescription.

West Palm Beach sits 18 miles north of RECO Health’s Delray Beach campus — roughly 28 minutes down I-95 or Federal Highway outside rush hour. For residents of El Cid, Flamingo Park, Northwood Hills, SoSo, and downtown WPB, the Delray campus is the closest specialist-level PHP and IOP program pairing in-house psychiatry with interventional options — rTMS and IV ketamine — on a single site. Depression care here is measurement-based, not impression-based: every plan begins with a DSM-5-TR diagnostic formulation and a baseline PHQ-9, and every plan is adjusted on the numbers.

Diagnostic formulation and severity staging

Depression is not a single condition, and treatment fails when the diagnosis is imprecise. The initial evaluation distinguishes major depressive disorder from persistent depressive disorder, bipolar II depression, adjustment disorder with depressed mood, and depression secondary to a general medical condition or substance use. Missing a bipolar spectrum diagnosis and initiating SSRI monotherapy can precipitate a mixed state or hypomania; missing a thyroid-driven presentation means chasing a mood disorder that no antidepressant will resolve.

Severity is anchored with the PHQ-9, supplemented by the GAD-7 for comorbid anxiety and the Columbia Suicide Severity Rating Scale (C-SSRS) at intake and every clinical touchpoint after. Admission labs include a thyroid panel with reflex free T4, vitamin B12, folate, vitamin D, and a comprehensive metabolic panel — not to replace psychiatric evaluation, but because untreated hypothyroidism or B12 deficiency will blunt any antidepressant response. Substance use, sleep architecture, and recent medication changes are screened as depression drivers before a treatment plan is written.

Level of care is matched to severity and safety. Partial hospitalization is indicated for PHQ-9 scores in the severe range (20 and above), for active suicidal ideation with plan or intent, or for functional collapse. Intensive outpatient is appropriate for moderate depression (PHQ-9 10-19) with adequate outpatient support and no acute risk.

Pharmacology sequenced by evidence, not habit

First-line pharmacotherapy for major depressive disorder is an SSRI (sertraline, escitalopram) or an SNRI (venlafaxine, duloxetine), initiated at a starter dose and titrated to therapeutic range within two to four weeks. Response is defined as a 50% reduction in PHQ-9 score; remission is a PHQ-9 below 5. Each trial is given four to six weeks at therapeutic dose before it is declared a failure — clients frequently arrive at our depression treatment program having been labeled “treatment-resistant” after subtherapeutic dosing or premature switches.

Partial responders are augmented rather than switched. Aripiprazole (2-5 mg), lithium (target level 0.6-0.8 mEq/L), bupropion, and low-dose quetiapine XR are evidence-based augmentation agents with STAR*D and CO-MED backing. Non-responders — no meaningful PHQ-9 movement at week six — are switched across mechanism (SSRI to SNRI, or either to bupropion or mirtazapine).

Treatment-resistant depression, defined as failure of two adequate antidepressant trials, is a staging decision — not a prompt to cycle through a fifth antidepressant. TRD clients are staged for rTMS, IV ketamine, or intranasal esketamine (Spravato) based on urgency, insurance, and clinical profile. Every medication decision is documented alongside the PHQ-9 trajectory and reviewed weekly in psychiatric rounds.

Behavioral therapy modalities with evidence for depression

Pharmacology alone produces remission in roughly half of major depression cases. The other half — and the durability of the first half — comes from structured psychotherapy. RECO’s therapists deliver Cognitive Behavioral Therapy for Depression to Beck’s protocol, targeting cognitive distortions (all-or-nothing thinking, catastrophizing, personalization) and the behavioral withdrawal that maintains anhedonia. Behavioral Activation is delivered as a discrete modality, not a technique folded into CBT — clients build activity hierarchies and track completion, because self-report about “feeling motivated” is a poor guide to what actually restores reward sensitivity.

Interpersonal Therapy is indicated when depression is anchored to grief, role transition, or persistent interpersonal conflict — common presentations in adults navigating divorce, caregiver strain, or job loss. Acceptance and Commitment Therapy is offered for clients whose depression is entangled with chronic pain, chronic illness, or values-level demoralization. For trauma-linked depression — a frequent finding in the substance-use population RECO also serves — Cognitive Processing Therapy or EMDR is layered in once acute symptoms are stabilized.

Group therapy at PHP and IOP levels supplements individual work but does not replace it. Every client carries a named individual therapist and a named psychiatric provider; group is the practice ground, not the whole intervention.

Escalation pathway when medication and therapy aren’t enough

Roughly one-third of clients with major depressive disorder will not achieve remission after two adequate antidepressant trials. The clinical error is not the non-response — it is drifting for months without a defined next step. The escalation pathway is laid out at intake and revisited at every treatment-plan review, so no client is left cycling through unhelpful medications while their function deteriorates.

Repetitive transcranial magnetic stimulation (rTMS) uses the FDA-cleared protocol: 10 Hz stimulation over the left dorsolateral prefrontal cortex at 120% of resting motor threshold, 3,000 pulses per session, 36 sessions across six to nine weeks. rTMS carries no systemic side effects, no cognitive burden, and no anesthesia — clients drive themselves in and out. Insurance coverage generally requires documented failure of at least four antidepressant trials plus one augmentation attempt.

Intravenous ketamine (0.5 mg/kg infused over 40 minutes, six-infusion induction across two to three weeks) is used when suicidality or functional collapse does not allow the six-to-nine-week rTMS course. Intranasal esketamine (Spravato) is available where a REMS-monitored, insurance-covered protocol is preferred. Every interventional patient is co-managed by psychiatry and a treating therapist — the point of a rapid antidepressant is to open a therapeutic window that psychotherapy consolidates into durable remission.

What to expect on your first visit

The first appointment is a 90-minute diagnostic evaluation with a psychiatric provider and a licensed clinician. History covers current symptoms, prior treatment (medications, doses, durations, response, side effects), family psychiatric history, substance use, medical comorbidities, and safety. The C-SSRS is administered; PHQ-9 and GAD-7 are documented as baselines. Labs are ordered if they have not been drawn in the past 90 days.

By the end of intake, clients leave with a working diagnosis, a recommended level of care, a treatment plan naming modalities and providers, and a scheduled follow-up. Prescription changes, when indicated, are started that day. West Palm Beach clients driving down for intake are placed into schedules that account for the 28-minute drive — most PHP and IOP tracks run mornings so clients are back home by early afternoon.

Insurance and admissions from West Palm Beach

RECO Health is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans commonly held by Palm Beach County residents. Verification of benefits is completed within one business day of the initial call — most West Palm Beach clients are scheduled for intake within 48 to 72 hours.

The admissions team confirms in-network status, PHP or IOP session authorization, and any prior-authorization requirements for rTMS or esketamine before the first appointment, so the treatment plan is not delayed by paperwork after clinical decisions have already been made.

Serving residents of: El Cid, Flamingo Park, Northwood Hills, SoSo, Downtown WPB.